CT-322 is a proprietary Adnectin(TM) protein therapeutic that, in preclinical studies, specifically binds to vascular endothelial growth factor receptor 2 (VEGFR-2), which regulates the primary tumor angiogenesis pathway. As a... As a result, CT-322 blocks all known ligands for VEGFR-2.
- Mechanism
- Curator reviewed
CT-322 specifically inhibits VEGFR-2 activation by its ligands VEGF-A, VEGF-C, and VEGF-D. In preclinical studies, this cell-surface receptor drives angiogenesis (growth of new blood vessels) in solid tumors, and CT-322 inhibits the tumorgenic effect of VEGFR-2 in preclinical models. CT-322 was designed using the PROfusion(TM) System, Adnexus' patented product design engine.
- Primary indication
- Investigated for use/treatment in cancer/tumors (unspecified) and macular degeneration.Curator reviewed
- Code names
- BMS-844203 · CT-322
Resolves to
What you can answer from here — as of June 15, 2026
Which drugs share a target with Pegdinetanib, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account